Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment

Am J Hematol. 2015 Jul;90(7):675-8. doi: 10.1002/ajh.23971. Epub 2015 Feb 27.
No abstract available

MeSH terms

  • Aged, 80 and over
  • Antibodies / blood
  • Anticoagulants / adverse effects*
  • Blood Platelets / drug effects
  • Blood Platelets / pathology
  • Dalteparin / adverse effects*
  • Female
  • Fondaparinux
  • Hip Fractures / blood
  • Hip Fractures / pathology
  • Hirudins
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Morpholines / therapeutic use
  • Peptide Fragments / therapeutic use
  • Platelet Count
  • Polysaccharides / adverse effects*
  • Recombinant Proteins / therapeutic use
  • Rivaroxaban
  • Thiophenes / therapeutic use
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / drug therapy
  • Thrombocytopenia / pathology*
  • Venous Thrombosis / blood
  • Venous Thrombosis / pathology
  • Venous Thrombosis / prevention & control

Substances

  • Antibodies
  • Anticoagulants
  • Hirudins
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Morpholines
  • Peptide Fragments
  • Polysaccharides
  • Recombinant Proteins
  • Thiophenes
  • Rivaroxaban
  • Fondaparinux
  • Dalteparin
  • bivalirudin